The AP5M1 Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population of A-549 cells with targeted disruption of the AP5M1 gene. This loss-of-function product provides a heterogeneous knockout pool that avoids clonal bias, suitable for studying AP5M1 function in an endogenous-like context. The polyclonal format preserves editing diversity and supports robust phenotypic characterization.
The parental A-549 cell line, derived from a 58-year-old male lung adenocarcinoma, exhibits wild-type p53 and a KRAS G12S mutation. These adherent epithelial cells model human alveolar type II epithelium and are extensively characterized as a gold standard for lung adenocarcinoma research, including investigations of oncogenic signaling and therapeutic resistance. The defined genetic background enhances the utility of the AP5M1 knockout for dissecting pathway interactions.
AP5M1 encodes the ?? subunit of adaptor protein complex 5 (AP-5), which mediates retrograde trafficking of CI-MPR from late endosomes to the Golgi. AP5M1 expression is regulated by TFEB and mTORC1. The AP-5 complex, including AP5B1, AP5Z1, and AP5S1, cooperates with clathrin, SPG11, and SPG15 to maintain lysosomal homeostasis. AP5M1 disruption abolishes complex assembly, causing CI-MPR mislocalization, lysosomal enzyme missorting, accumulation of autophagic substrates, and impaired autophagy, recapitulating molecular defects observed in hereditary spastic paraplegia type 48 (SPG48).
In the A-549 background, this model enables investigation of AP-5-dependent endosomal trafficking in a cancer context. The interplay between KRAS-driven oncogenesis and lysosomal dysfunction can be studied through autophagy flux assays, migration/invasion tests, and lysosomal activity measurements. The polyclonal nature reflects genetic heterogeneity, making it valuable for drug screening and biomarker discovery in neurodegenerative and lysosomal storage disorders.
Researchers can utilize this polyclonal knockout for western blot detection of AP5M1, LC3-II, and p62; immunofluorescence colocalization of CI-MPR with LAMP1; and co-immunoprecipitation to assess AP-5 complex integrity. Autophagic flux and lysosomal enzyme assays further define functional outcomes. The model is also amenable to high-throughput screening of compounds targeting trafficking pathways. For additional information, please contact Ascent Research.
